West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) - Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for shares of West Pharmaceutical Services in a research note issued on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings per share of $1.50 for the quarter, up from their previous forecast of $1.44. The consensus estimate for West Pharmaceutical Services' current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services' Q3 2025 earnings at $1.61 EPS, Q3 2026 earnings at $1.86 EPS, Q4 2026 earnings at $1.93 EPS and Q1 2027 earnings at $1.44 EPS.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.23. The company had revenue of $698.00 million during the quarter, compared to analysts' expectations of $685.24 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. West Pharmaceutical Services's revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter last year, the company earned $1.56 EPS.
A number of other equities analysts have also recently commented on WST. Evercore ISI initiated coverage on West Pharmaceutical Services in a report on Tuesday, March 18th. They set an "outperform" rating and a $275.00 price target for the company. Stephens upgraded West Pharmaceutical Services to a "strong-buy" rating in a report on Monday, April 21st. KeyCorp reduced their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 price target for the company in a report on Friday, February 14th. Finally, StockNews.com cut West Pharmaceutical Services from a "buy" rating to a "hold" rating in a report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $332.50.
View Our Latest Stock Report on WST
West Pharmaceutical Services Stock Up 0.2%
Shares of NYSE WST traded up $0.36 during mid-day trading on Friday, hitting $217.00. The company had a trading volume of 535,635 shares, compared to its average volume of 727,647. The company has a market capitalization of $15.59 billion, a PE ratio of 32.44, a price-to-earnings-growth ratio of 6.74 and a beta of 1.14. The firm has a 50-day simple moving average of $214.75 and a two-hundred day simple moving average of $273.88. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services has a one year low of $187.43 and a one year high of $355.66.
West Pharmaceutical Services Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio is presently 13.19%.
Institutional Investors Weigh In On West Pharmaceutical Services
A number of institutional investors have recently made changes to their positions in WST. Whipplewood Advisors LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $25,000. Zions Bancorporation National Association UT acquired a new stake in shares of West Pharmaceutical Services in the first quarter valued at approximately $25,000. Quarry LP acquired a new stake in shares of West Pharmaceutical Services in the first quarter valued at approximately $27,000. Retirement Wealth Solutions LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $34,000. Finally, Centricity Wealth Management LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $35,000. Institutional investors own 93.90% of the company's stock.
West Pharmaceutical Services Company Profile
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
